Abstract. The 
It is concluded that 1) subjects suspected of harbouring a microprolactinoma (groups I and II) demonstrate absent or attenuated responses similar to those found in patients with definite prolactinomas and 2) a value of plasma Prl 20 min after 200 \ g=m\ g TRH iv greater than 3.5 times the basal level (R2 > 2.5) rules out the presence of a prolactinoma.
Hyperprolactinaemia can be either tumoural or non-tumoural in origin (Frantz et al. 1972; Child et al. 1975; 1976; Gomez et al. 1977) . While some patients with prolactin (Prl) producing ade¬ nomas ('prolactinomas') ('micro-adenomas') that the height of the plasma Prl concentration and routine or even specialized radiographie proce¬ dures (such as hypocycloidal polytomography) are at best of dubious diagnostic value. Thorner ( 1977) , and Silvestrini et al. (1978) have recently reviewed this problem.
Although it must be realized that the natural history of the alleged microadenomas is completely 
Prl-assay
Plasma Prl was measured in duplicate by radioimmuno¬ assay as reported previously (Assies et al. 1978) . The upper limits of normal women and men are 20 and 15 ng/ml, respectively. If only one of the 3 'basal' plasma samples (-15, 0 and 240 min) slightly exceeded the upper limit, the subject was included in the control group.
Calculations
The Prl response to TRH was estimated using two different methods:
In the first method the sum of the basal plasma Prl The inner limits of the percentiles P 2.5 and P 97.5 of the ratios 1 and 2 of all groups and of the various plasma values of the control groups, were calculated with a distribution free method with a confidence of 90% according to Elveback & Taylor (1969) and Rümke 8c Bezemer (1972) . Plasma Prl concentrations below the detection limit of the assay (2 ng/ml) were taken as 2 ng/ml. 
Results
The Prl response to TRH of the normal subjects (range, median, P 2.5 and P 97.5, Ri and R2) is presented in Table 1 and depicted in Fig. 1 In contrast, subjects with unequivocal evidence of a prolactinoma (groups III, IV and V) have a much lower response. In fact, none of these pa¬ tients had an R2 value greater than 2.5 (Fig. 3) . It is clear from the results depicted in Figs. 2 and 3 that the response expressed as R2 has more discriminat¬ ing value than Ri. Thus, a 20 min Prl response after 200 ug TRH higher than 3.5 times the basal level was never observed in our tumour patients and only 5 out of 42 patients (12%) showed a peak level higher than 2 times the basal level (R2 > 1). This is again in accordance with the results re¬ ported by others; irrespective of the dose of TRH used, the response of tumour patients does not exceed the 3.5 times basal value (Jacobs & (Aubert et al. 1975; Delitala et al. 1978; Tyson 8c Friesen 1973; Vandalem et al. 1977; Ylikorkala et al. 1979; Jeppson et al. 1976; Bowers et al. 1973; Rutlin et al. 1977; Snyder et al. 1973) .
Although a diminished response is thus highly suggestive for the presence of a (micro)prolactinoma, it is to be noted that a failure of TRH to modulate the Prl secretion has also been reported in various other clinical conditions, viz. hyperthyroidism, alcoholic livercirrhosis, chronic renal failure and obesity (Onishi et al. 1975; Van Thiel et al. 1978; Czernichow et al. 1976; Lim et al. 1979; Kopelman et al. 1979 (Neill 1974) (Frantz et al. 1972; Kleinberg et al. 1977; Thorner 1977) , however, metoclopramide has been reported to stimulate Prl secretion strongly and consistently in normal subjects but not in prolactinoma patients (Cowden et al. 1979; Jeske 1979 
